Last reviewed · How we verify
Conventional drugs
Conventional drugs is a Conventional drug Small molecule drug developed by University of Science and Technology, Yemen. It is currently in Phase 3 development for Hypertension. Also known as: Amoxicillin, Metronidazole, and Diclofenac sodium, cyproheptadine.
This drug works by inhibiting the action of a specific enzyme.
Conventional drugs, specifically I-123 Ioflupane solution injection, are used to diagnose conditions such as dementia, Parkinsonism, and REM Sleep Behavior Disorder through a DaTscan imaging procedure. I-123 Ioflupane solution injection targets the methotrexate hydrolytic enzyme, which is involved in the breakdown of folate.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Conventional drugs |
|---|---|
| Also known as | Amoxicillin, Metronidazole, and Diclofenac sodium, cyproheptadine |
| Sponsor | University of Science and Technology, Yemen |
| Drug class | Conventional drug |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism is not well understood, but it is thought to involve the inhibition of this enzyme, leading to a decrease in the production of a certain compound. This decrease in production is believed to be responsible for the therapeutic effects of the drug.
Approved indications
- Hypertension
Common side effects
- Headache
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1, PHASE2)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) (PHASE2)
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) (PHASE2)
- Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional drugs CI brief — competitive landscape report
- Conventional drugs updates RSS · CI watch RSS
- University of Science and Technology, Yemen portfolio CI
Frequently asked questions about Conventional drugs
What is Conventional drugs?
How does Conventional drugs work?
What is Conventional drugs used for?
Who makes Conventional drugs?
Is Conventional drugs also known as anything else?
What drug class is Conventional drugs in?
What development phase is Conventional drugs in?
What are the side effects of Conventional drugs?
Related
- Drug class: All Conventional drug drugs
- Manufacturer: University of Science and Technology, Yemen — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Also known as: Amoxicillin, Metronidazole, and Diclofenac sodium, cyproheptadine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing